Live Breaking News & Updates on Nasdaq Xfor|Page 2

Stay updated with breaking news from Nasdaq xfor. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Q3 2023 EPS Estimates for X4 Pharmaceuticals, Inc. Lifted by Analyst (NASDAQ:XFOR)

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR – Free Report) – Analysts at Zacks Small Cap boosted their Q3 2023 earnings per share (EPS) estimates for shares of X4 Pharmaceuticals in a research note issued to investors on Tuesday, August 15th. Zacks Small Cap analyst D. Bautz now expects that the company will post earnings per share of […] ....

Stifel Nicolaus , Murray Stewart , Wells Fargo Company , Pharmaceuticals Inc , Pharmaceuticals Daily , Stonepine Capital Management , Pharmaceuticals Price Performance , Nuveen Asset Management , Pharmaceuticals Company Profile , Goldman Sachs Group Inc , Free Report , Zacks Small Cap , Small Cap , Get Free Report , Asset Management , Capital Management , Goldman Sachs Group , Sachs Group , X4 Pharmaceuticals , Nasdaq Xfor , Earnings Estimates ,

X4 Pharmaceuticals (NASDAQ:XFOR) Announces Earnings Results

X4 Pharmaceuticals (NASDAQ:XFOR – Get Free Report) issued its earnings results on Thursday. The company reported ($0.33) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.16), MarketWatch Earnings reports. During the same quarter last year, the company earned ($0.60) earnings per share. X4 Pharmaceuticals Price Performance Shares of XFOR stock […] ....

Stifel Nicolaus , Murray Stewart , Pharmaceuticals Price Performance , Vanguard Group Inc , Securities Exchange Commission , Millennium Management , Blackrock Inc , Perceptive Advisors , Pharmaceuticals Inc , Geode Capital Management , Pharmaceuticals Daily , Get Free Report , Marketwatch Earnings , Exchange Commission , Capital Management , X4 Pharmaceuticals , Nasdaq Xfor ,

HC Wainwright Reiterates "Buy" Rating for X4 Pharmaceuticals (NASDAQ:XFOR)

HC Wainwright restated their buy rating on shares of X4 Pharmaceuticals (NASDAQ:XFOR – Free Report) in a research note issued to investors on Friday, Benzinga reports. The firm currently has a $3.00 price target on the stock. Separately, Stifel Nicolaus boosted their price objective on shares of X4 Pharmaceuticals from $4.00 to $5.00 in a […] ....

Stifel Nicolaus , Murray Stewart , Blackrock Inc , Pharmaceuticals Inc , Vanguard Group Inc , Management Company , Pharmaceuticals Daily , Perceptive Advisors , Securities Exchange Commission , Pharmaceuticals Price Performance , Free Report , Get Free Report , Exchange Commission , Vanguard Group , X4 Pharmaceuticals , Nasdaq Xfor , Reiterated Rating , Hc Wainwright ,

X4 Pharmaceuticals (XFOR) Set to Announce Quarterly Earnings on Thursday

X4 Pharmaceuticals (NASDAQ:XFOR – Get Free Report) is scheduled to be posting its 6/30/2023 quarterly earnings results before the market opens on Thursday, August 10th. Analysts expect X4 Pharmaceuticals to post earnings of ($0.17) per share for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this […] ....

Stifel Nicolaus , Blackrock Inc , York Mellon Corp , Pharmaceuticals Inc , Renaissance Technologies , Jpmorgan Chase Co , Pharmaceuticals Daily , Pharmaceuticals Stock , Barclays Plc , Get Free Report , New York Mellon Corp , X4 Pharmaceuticals , Nasdaq Xfor ,

Paula Ragan Sells 6,724 Shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Stock

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR – Get Rating) CEO Paula Ragan sold 6,724 shares of the firm’s stock in a transaction on Friday, June 23rd. The shares were sold at an average price of $1.92, for a total transaction of $12,910.08. Following the completion of the transaction, the chief executive officer now directly owns 543,797 shares […] ....

Stifel Nicolaus , Paula Ragan , Securities Exchange Commission , Pharmaceuticals Company Profile , Perceptive Advisors , Bain Capital Life Sciences Investors , Cantor Fitzgerald , Pharmaceuticals Daily , Management Company , Vanguard Group Inc , Pharmaceuticals Trading Down , Lynwood Capital Management Inc , Pharmaceuticals Inc , Get Rating , Exchange Commission , Trading Down , Capital Life Sciences Investors , Lynwood Capital Management , X4 Pharmaceuticals , Nasdaq Xfor , Insider Trading , Nsider Trades ,